VEGF (Vascular Endothelial Growth Factor) is a critical driver of tumor angiogenesis and pathological neovascularization in diseases such as:
Antibody-based VEGF inhibitors (e.g., bevacizumab, ranibizumab) have improved treatment outcomes, but key challenges remain:
Researchers, CROs, and biopharma developers seek novel VEGF-binding aptamers as cost-effective, specific, and stable alternatives for oncology and ophthalmology applications.